Acute myocardial infarction treated with novel Resolute Onyx and Orsiro stents in the randomized BIONYX trial.
clinical trials
drug-eluting stent
myocardial infarction
percutaneous coronary intervention
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
revised:
01
02
2021
received:
14
10
2020
accepted:
19
02
2021
pubmed:
12
3
2021
medline:
21
10
2021
entrez:
11
3
2021
Statut:
ppublish
Résumé
To compare 2-year outcome following treatment with drug-eluting stents (DES) for acute myocardial infarction (MI) versus non-MI clinical syndromes. In acute MI patients, a stent-level comparison was performed, comparing Resolute Onyx versus Orsiro stents. In patients presenting with acute MI, higher adverse event rates have been reported. So far, no clinical results >1 year have been published of acute MI patients treated with Resolute Onyx. This post-hoc analysis of the randomized BIONYX trial(NCT02508714) assessed the main outcome target vessel failure (TVF: cardiac death, target vessel MI, or target vessel revascularization) with Kaplan-Meier methods. Of all 2,488 trial participants, acute MI patients (n = 1,275[51.2%]) were significantly younger and had less comorbidities than non-MI patients (n = 1,213[48.8%]). TVF rates were lower in acute MI patients (77/1,275[6.1%] vs. 103/1,213[8.6%], HR:0.70, 95%-CI 0.52-0.94; p Two years after treatment with thin-strut DES in this randomized trial, patients treated for acute MI had lower adverse event rates than non-MI patients. Yet, these findings were mainly attributable to between-group differences in patient and lesion characteristics. In patients who underwent PCI for acute MI, both Resolute Onyx and Orsiro showed favorable and similar 2-year outcomes.
Sections du résumé
OBJECTIVES
To compare 2-year outcome following treatment with drug-eluting stents (DES) for acute myocardial infarction (MI) versus non-MI clinical syndromes. In acute MI patients, a stent-level comparison was performed, comparing Resolute Onyx versus Orsiro stents.
BACKGROUND
In patients presenting with acute MI, higher adverse event rates have been reported. So far, no clinical results >1 year have been published of acute MI patients treated with Resolute Onyx.
METHODS
This post-hoc analysis of the randomized BIONYX trial(NCT02508714) assessed the main outcome target vessel failure (TVF: cardiac death, target vessel MI, or target vessel revascularization) with Kaplan-Meier methods.
RESULTS
Of all 2,488 trial participants, acute MI patients (n = 1,275[51.2%]) were significantly younger and had less comorbidities than non-MI patients (n = 1,213[48.8%]). TVF rates were lower in acute MI patients (77/1,275[6.1%] vs. 103/1,213[8.6%], HR:0.70, 95%-CI 0.52-0.94; p
CONCLUSIONS
Two years after treatment with thin-strut DES in this randomized trial, patients treated for acute MI had lower adverse event rates than non-MI patients. Yet, these findings were mainly attributable to between-group differences in patient and lesion characteristics. In patients who underwent PCI for acute MI, both Resolute Onyx and Orsiro showed favorable and similar 2-year outcomes.
Identifiants
pubmed: 33694294
doi: 10.1002/ccd.29594
pmc: PMC8451772
doi:
Substances chimiques
Everolimus
9HW64Q8G6G
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
E188-E196Subventions
Organisme : Biotronik
Organisme : Medtronic
Informations de copyright
© 2021 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.
Références
Catheter Cardiovasc Interv. 2017 Aug 1;90(2):E31-E37
pubmed: 28145609
Catheter Cardiovasc Interv. 2018 Aug 1;92(2):253-259
pubmed: 28940882
Circulation. 2008 Sep 9;118(11):1138-45
pubmed: 18725485
Rev Esp Cardiol (Engl Ed). 2016 Dec;69(12):1152-1159
pubmed: 27595181
Circ Cardiovasc Interv. 2019 Sep;12(9):e008152
pubmed: 31451014
EuroIntervention. 2010 Feb;5(7):871-4
pubmed: 20142206
Cardiol J. 2019;26(5):469-476
pubmed: 29745969
Postepy Kardiol Interwencyjnej. 2018;14(4):347-355
pubmed: 30603024
JACC Cardiovasc Interv. 2016 May 9;9(9):981-3
pubmed: 27151616
Eur J Clin Invest. 2012 Oct;42(10):1047-54
pubmed: 22624990
J Interv Cardiol. 2019 Nov 3;2019:3146848
pubmed: 31777468
Catheter Cardiovasc Interv. 2021 Aug 1;98(2):E188-E196
pubmed: 33694294
Lancet. 2018 Oct 6;392(10154):1235-1245
pubmed: 30253879
Circulation. 2007 May 1;115(17):2344-51
pubmed: 17470709
Eur Heart J. 2012 May;33(10):1214-22
pubmed: 22447805
Int J Cardiol. 2021 Mar 15;327:52-57
pubmed: 33242506
Lancet. 2007 Feb 24;369(9562):667-78
pubmed: 17321312
Int J Cardiol. 2013 Oct 9;168(4):3522-6
pubmed: 23706326
J Am Coll Cardiol. 2018 Dec 25;72(25):3287-3297
pubmed: 30257191
J Am Coll Cardiol. 2014 Jul 8;64(1):16-24
pubmed: 24998123
Eur Heart J. 2012 Oct;33(20):2551-67
pubmed: 22922414
Lancet. 2016 Jan 23;387(10016):357-366
pubmed: 26520230
Catheter Cardiovasc Interv. 2019 Dec 1;94(7):972-979
pubmed: 31037840
Lancet. 2019 Oct 5;394(10205):1243-1253
pubmed: 31488372
EuroIntervention. 2019 Apr 05;14(18):e1836-e1842
pubmed: 29957593
EuroIntervention. 2014 Jun;10(2):212-23
pubmed: 23838425
Circulation. 2012 Mar 6;125(9):1110-21
pubmed: 22302840
Circ Cardiovasc Interv. 2013 Aug;6(4):378-90
pubmed: 23922145
JACC Cardiovasc Interv. 2020 May 11;13(9):1100-1109
pubmed: 32381186
EuroIntervention. 2016 Dec 10;12(11):e1343-e1354
pubmed: 26690319
Am J Cardiol. 2015 Jul 1;116(1):15-23
pubmed: 26068701
JACC Cardiovasc Interv. 2011 Oct;4(10):1104-15
pubmed: 22017936
J Am Heart Assoc. 2016 Mar 15;5(3):e003255
pubmed: 26979080
JACC Cardiovasc Interv. 2015 Jun;8(7):889-99
pubmed: 26003019
Eur Heart J. 2019 Jun 21;40(24):1909-1919
pubmed: 30851032